0.013556 0.000000 0.000000 0.000000 0.013784 0.000000 0.000000 0.000000 0.018498 0.00000 0.00000 0.00000 Schulze-Gahmen, U. Meijer, L. Kim, S.-H. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 4 90.00 90.00 90.00 73.770 72.550 54.060 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C15 H18 N6 O 298.343 OLOMOUCINE non-polymer C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proteins PSFGEY 0867 0887-3585 22 378 10.1002/PROT.340220408 7479711 Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. 1995 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 287.0 1 MIRRORS IMAGE PLATE RIGAKU IMAGE PLATE SINGLE WAVELENGTH M x-ray 1 1.5418 1.0 1.5418 ROTATING ANODE RIGAKU RU200 INHIBITOR BOUND IN POCKET BETWEEN 2 DOMAINS 33976.488 CYCLIN-DEPENDENT KINASE 2 2.7.1.37 1 man polymer 298.343 OLOMOUCINE 1 syn non-polymer 18.015 water 76 nat water P33 PROTEIN KINASE, CDK2 no no MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL C polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN FALL ARMYWORM sample 9606 HOMO SAPIENS SF9 7108 SPODOPTERA FRUGIPERDA BACULOVIRUS 1 2.13 42.22 repository Initial release Database references Derived calculations Non-polymer description Other Source and taxonomy Structure summary Version format compliance 1 0 2005-01-14 1 1 2014-02-05 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A P27(KIP1)/CYCLIN A/CDK2 COMPLEX THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P-F-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-AMINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-AMINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,4-DIAMINE PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 PDBE Y PDBE 2004-06-14 REL OLO OLOMOUCINE HOH water FUNCTION: PROBABLY INVOLVED IN THE CONTROL OF THE CELL CYCLE. INTERACTS WITH CYCLINS A, B3, D, OR E. ACTIVITY OF CDK2 IS MAXIMAL DURING S PHASE AND G2. CATALYTIC ACTIVITY: ATP + A PROTEIN = ADP + A PHOSPHOPROTEIN. OLO 1299 2 OLO OLO 1299 C HOH 2001 3 HOH HOH 2001 C HOH 2002 3 HOH HOH 2002 C HOH 2003 3 HOH HOH 2003 C HOH 2004 3 HOH HOH 2004 C HOH 2005 3 HOH HOH 2005 C HOH 2006 3 HOH HOH 2006 C HOH 2007 3 HOH HOH 2007 C HOH 2008 3 HOH HOH 2008 C HOH 2009 3 HOH HOH 2009 C HOH 2010 3 HOH HOH 2010 C HOH 2011 3 HOH HOH 2011 C HOH 2012 3 HOH HOH 2012 C HOH 2013 3 HOH HOH 2013 C HOH 2014 3 HOH HOH 2014 C HOH 2015 3 HOH HOH 2015 C HOH 2016 3 HOH HOH 2016 C HOH 2017 3 HOH HOH 2017 C HOH 2018 3 HOH HOH 2018 C HOH 2019 3 HOH HOH 2019 C HOH 2020 3 HOH HOH 2020 C HOH 2021 3 HOH HOH 2021 C HOH 2022 3 HOH HOH 2022 C HOH 2023 3 HOH HOH 2023 C HOH 2024 3 HOH HOH 2024 C HOH 2025 3 HOH HOH 2025 C HOH 2026 3 HOH HOH 2026 C HOH 2027 3 HOH HOH 2027 C HOH 2028 3 HOH HOH 2028 C HOH 2029 3 HOH HOH 2029 C HOH 2030 3 HOH HOH 2030 C HOH 2031 3 HOH HOH 2031 C HOH 2032 3 HOH HOH 2032 C HOH 2033 3 HOH HOH 2033 C HOH 2034 3 HOH HOH 2034 C HOH 2035 3 HOH HOH 2035 C HOH 2036 3 HOH HOH 2036 C HOH 2037 3 HOH HOH 2037 C HOH 2038 3 HOH HOH 2038 C HOH 2039 3 HOH HOH 2039 C HOH 2040 3 HOH HOH 2040 C HOH 2041 3 HOH HOH 2041 C HOH 2042 3 HOH HOH 2042 C HOH 2043 3 HOH HOH 2043 C HOH 2044 3 HOH HOH 2044 C HOH 2045 3 HOH HOH 2045 C HOH 2046 3 HOH HOH 2046 C HOH 2047 3 HOH HOH 2047 C HOH 2048 3 HOH HOH 2048 C HOH 2049 3 HOH HOH 2049 C HOH 2050 3 HOH HOH 2050 C HOH 2051 3 HOH HOH 2051 C HOH 2052 3 HOH HOH 2052 C HOH 2053 3 HOH HOH 2053 C HOH 2054 3 HOH HOH 2054 C HOH 2055 3 HOH HOH 2055 C HOH 2056 3 HOH HOH 2056 C HOH 2057 3 HOH HOH 2057 C HOH 2058 3 HOH HOH 2058 C HOH 2059 3 HOH HOH 2059 C HOH 2060 3 HOH HOH 2060 C HOH 2061 3 HOH HOH 2061 C HOH 2062 3 HOH HOH 2062 C HOH 2063 3 HOH HOH 2063 C HOH 2064 3 HOH HOH 2064 C HOH 2065 3 HOH HOH 2065 C HOH 2066 3 HOH HOH 2066 C HOH 2067 3 HOH HOH 2067 C HOH 2068 3 HOH HOH 2068 C HOH 2069 3 HOH HOH 2069 C HOH 2070 3 HOH HOH 2070 C HOH 2071 3 HOH HOH 2071 C HOH 2072 3 HOH HOH 2072 C HOH 2073 3 HOH HOH 2073 C HOH 2074 3 HOH HOH 2074 C HOH 2075 3 HOH HOH 2075 C HOH 2076 3 HOH HOH 2076 C MET 1 n 1 MET 1 C GLU 2 n 2 GLU 2 C ASN 3 n 3 ASN 3 C PHE 4 n 4 PHE 4 C GLN 5 n 5 GLN 5 C LYS 6 n 6 LYS 6 C VAL 7 n 7 VAL 7 C GLU 8 n 8 GLU 8 C LYS 9 n 9 LYS 9 C ILE 10 n 10 ILE 10 C GLY 11 n 11 GLY 11 C GLU 12 n 12 GLU 12 C GLY 13 n 13 GLY 13 C THR 14 n 14 THR 14 C TYR 15 n 15 TYR 15 C GLY 16 n 16 GLY 16 C VAL 17 n 17 VAL 17 C VAL 18 n 18 VAL 18 C TYR 19 n 19 TYR 19 C LYS 20 n 20 LYS 20 C ALA 21 n 21 ALA 21 C ARG 22 n 22 ARG 22 C ASN 23 n 23 ASN 23 C LYS 24 n 24 LYS 24 C LEU 25 n 25 LEU 25 C THR 26 n 26 THR 26 C GLY 27 n 27 GLY 27 C GLU 28 n 28 GLU 28 C VAL 29 n 29 VAL 29 C VAL 30 n 30 VAL 30 C ALA 31 n 31 ALA 31 C LEU 32 n 32 LEU 32 C LYS 33 n 33 LYS 33 C LYS 34 n 34 LYS 34 C ILE 35 n 35 ILE 35 C ARG 36 n 36 ARG 36 C n 37 37 C n 38 38 C n 39 39 C n 40 40 C n 41 41 C n 42 42 C n 43 43 C VAL 44 n 44 VAL 44 C PRO 45 n 45 PRO 45 C SER 46 n 46 SER 46 C THR 47 n 47 THR 47 C ALA 48 n 48 ALA 48 C ILE 49 n 49 ILE 49 C ARG 50 n 50 ARG 50 C GLU 51 n 51 GLU 51 C ILE 52 n 52 ILE 52 C SER 53 n 53 SER 53 C LEU 54 n 54 LEU 54 C LEU 55 n 55 LEU 55 C LYS 56 n 56 LYS 56 C GLU 57 n 57 GLU 57 C LEU 58 n 58 LEU 58 C ASN 59 n 59 ASN 59 C HIS 60 n 60 HIS 60 C PRO 61 n 61 PRO 61 C ASN 62 n 62 ASN 62 C ILE 63 n 63 ILE 63 C VAL 64 n 64 VAL 64 C LYS 65 n 65 LYS 65 C LEU 66 n 66 LEU 66 C LEU 67 n 67 LEU 67 C ASP 68 n 68 ASP 68 C VAL 69 n 69 VAL 69 C ILE 70 n 70 ILE 70 C HIS 71 n 71 HIS 71 C THR 72 n 72 THR 72 C GLU 73 n 73 GLU 73 C ASN 74 n 74 ASN 74 C LYS 75 n 75 LYS 75 C LEU 76 n 76 LEU 76 C TYR 77 n 77 TYR 77 C LEU 78 n 78 LEU 78 C VAL 79 n 79 VAL 79 C PHE 80 n 80 PHE 80 C GLU 81 n 81 GLU 81 C PHE 82 n 82 PHE 82 C LEU 83 n 83 LEU 83 C HIS 84 n 84 HIS 84 C GLN 85 n 85 GLN 85 C ASP 86 n 86 ASP 86 C LEU 87 n 87 LEU 87 C LYS 88 n 88 LYS 88 C LYS 89 n 89 LYS 89 C PHE 90 n 90 PHE 90 C MET 91 n 91 MET 91 C ASP 92 n 92 ASP 92 C ALA 93 n 93 ALA 93 C SER 94 n 94 SER 94 C ALA 95 n 95 ALA 95 C LEU 96 n 96 LEU 96 C THR 97 n 97 THR 97 C GLY 98 n 98 GLY 98 C ILE 99 n 99 ILE 99 C PRO 100 n 100 PRO 100 C LEU 101 n 101 LEU 101 C PRO 102 n 102 PRO 102 C LEU 103 n 103 LEU 103 C ILE 104 n 104 ILE 104 C LYS 105 n 105 LYS 105 C SER 106 n 106 SER 106 C TYR 107 n 107 TYR 107 C LEU 108 n 108 LEU 108 C PHE 109 n 109 PHE 109 C GLN 110 n 110 GLN 110 C LEU 111 n 111 LEU 111 C LEU 112 n 112 LEU 112 C GLN 113 n 113 GLN 113 C GLY 114 n 114 GLY 114 C LEU 115 n 115 LEU 115 C ALA 116 n 116 ALA 116 C PHE 117 n 117 PHE 117 C CYS 118 n 118 CYS 118 C HIS 119 n 119 HIS 119 C SER 120 n 120 SER 120 C HIS 121 n 121 HIS 121 C ARG 122 n 122 ARG 122 C VAL 123 n 123 VAL 123 C LEU 124 n 124 LEU 124 C HIS 125 n 125 HIS 125 C ARG 126 n 126 ARG 126 C ASP 127 n 127 ASP 127 C LEU 128 n 128 LEU 128 C LYS 129 n 129 LYS 129 C PRO 130 n 130 PRO 130 C GLN 131 n 131 GLN 131 C ASN 132 n 132 ASN 132 C LEU 133 n 133 LEU 133 C LEU 134 n 134 LEU 134 C ILE 135 n 135 ILE 135 C ASN 136 n 136 ASN 136 C THR 137 n 137 THR 137 C GLU 138 n 138 GLU 138 C GLY 139 n 139 GLY 139 C ALA 140 n 140 ALA 140 C ILE 141 n 141 ILE 141 C LYS 142 n 142 LYS 142 C LEU 143 n 143 LEU 143 C ALA 144 n 144 ALA 144 C ASP 145 n 145 ASP 145 C PHE 146 n 146 PHE 146 C GLY 147 n 147 GLY 147 C LEU 148 n 148 LEU 148 C ALA 149 n 149 ALA 149 C ARG 150 n 150 ARG 150 C ALA 151 n 151 ALA 151 C PHE 152 n 152 PHE 152 C n 153 153 C n 154 154 C n 155 155 C n 156 156 C n 157 157 C n 158 158 C n 159 159 C n 160 160 C n 161 161 C n 162 162 C n 163 163 C VAL 164 n 164 VAL 164 C THR 165 n 165 THR 165 C LEU 166 n 166 LEU 166 C TRP 167 n 167 TRP 167 C TYR 168 n 168 TYR 168 C ARG 169 n 169 ARG 169 C ALA 170 n 170 ALA 170 C PRO 171 n 171 PRO 171 C GLU 172 n 172 GLU 172 C ILE 173 n 173 ILE 173 C LEU 174 n 174 LEU 174 C LEU 175 n 175 LEU 175 C GLY 176 n 176 GLY 176 C CYS 177 n 177 CYS 177 C LYS 178 n 178 LYS 178 C TYR 179 n 179 TYR 179 C TYR 180 n 180 TYR 180 C SER 181 n 181 SER 181 C THR 182 n 182 THR 182 C ALA 183 n 183 ALA 183 C VAL 184 n 184 VAL 184 C ASP 185 n 185 ASP 185 C ILE 186 n 186 ILE 186 C TRP 187 n 187 TRP 187 C SER 188 n 188 SER 188 C LEU 189 n 189 LEU 189 C GLY 190 n 190 GLY 190 C CYS 191 n 191 CYS 191 C ILE 192 n 192 ILE 192 C PHE 193 n 193 PHE 193 C ALA 194 n 194 ALA 194 C GLU 195 n 195 GLU 195 C MET 196 n 196 MET 196 C VAL 197 n 197 VAL 197 C THR 198 n 198 THR 198 C ARG 199 n 199 ARG 199 C ARG 200 n 200 ARG 200 C ALA 201 n 201 ALA 201 C LEU 202 n 202 LEU 202 C PHE 203 n 203 PHE 203 C PRO 204 n 204 PRO 204 C GLY 205 n 205 GLY 205 C ASP 206 n 206 ASP 206 C SER 207 n 207 SER 207 C GLU 208 n 208 GLU 208 C ILE 209 n 209 ILE 209 C ASP 210 n 210 ASP 210 C GLN 211 n 211 GLN 211 C LEU 212 n 212 LEU 212 C PHE 213 n 213 PHE 213 C ARG 214 n 214 ARG 214 C ILE 215 n 215 ILE 215 C PHE 216 n 216 PHE 216 C ARG 217 n 217 ARG 217 C THR 218 n 218 THR 218 C LEU 219 n 219 LEU 219 C GLY 220 n 220 GLY 220 C THR 221 n 221 THR 221 C PRO 222 n 222 PRO 222 C ASP 223 n 223 ASP 223 C GLU 224 n 224 GLU 224 C VAL 225 n 225 VAL 225 C VAL 226 n 226 VAL 226 C TRP 227 n 227 TRP 227 C PRO 228 n 228 PRO 228 C GLY 229 n 229 GLY 229 C VAL 230 n 230 VAL 230 C THR 231 n 231 THR 231 C SER 232 n 232 SER 232 C MET 233 n 233 MET 233 C PRO 234 n 234 PRO 234 C ASP 235 n 235 ASP 235 C TYR 236 n 236 TYR 236 C LYS 237 n 237 LYS 237 C PRO 238 n 238 PRO 238 C SER 239 n 239 SER 239 C PHE 240 n 240 PHE 240 C PRO 241 n 241 PRO 241 C LYS 242 n 242 LYS 242 C TRP 243 n 243 TRP 243 C ALA 244 n 244 ALA 244 C ARG 245 n 245 ARG 245 C GLN 246 n 246 GLN 246 C ASP 247 n 247 ASP 247 C PHE 248 n 248 PHE 248 C SER 249 n 249 SER 249 C LYS 250 n 250 LYS 250 C VAL 251 n 251 VAL 251 C VAL 252 n 252 VAL 252 C PRO 253 n 253 PRO 253 C PRO 254 n 254 PRO 254 C LEU 255 n 255 LEU 255 C ASP 256 n 256 ASP 256 C GLU 257 n 257 GLU 257 C ASP 258 n 258 ASP 258 C GLY 259 n 259 GLY 259 C ARG 260 n 260 ARG 260 C SER 261 n 261 SER 261 C LEU 262 n 262 LEU 262 C LEU 263 n 263 LEU 263 C SER 264 n 264 SER 264 C GLN 265 n 265 GLN 265 C MET 266 n 266 MET 266 C LEU 267 n 267 LEU 267 C HIS 268 n 268 HIS 268 C TYR 269 n 269 TYR 269 C ASP 270 n 270 ASP 270 C PRO 271 n 271 PRO 271 C ASN 272 n 272 ASN 272 C LYS 273 n 273 LYS 273 C ARG 274 n 274 ARG 274 C ILE 275 n 275 ILE 275 C SER 276 n 276 SER 276 C ALA 277 n 277 ALA 277 C LYS 278 n 278 LYS 278 C ALA 279 n 279 ALA 279 C ALA 280 n 280 ALA 280 C LEU 281 n 281 LEU 281 C ALA 282 n 282 ALA 282 C HIS 283 n 283 HIS 283 C PRO 284 n 284 PRO 284 C PHE 285 n 285 PHE 285 C PHE 286 n 286 PHE 286 C GLN 287 n 287 GLN 287 C ASP 288 n 288 ASP 288 C VAL 289 n 289 VAL 289 C THR 290 n 290 THR 290 C LYS 291 n 291 LYS 291 C PRO 292 n 292 PRO 292 C VAL 293 n 293 VAL 293 C PRO 294 n 294 PRO 294 C HIS 295 n 295 HIS 295 C LEU 296 n 296 LEU 296 C ARG 297 n 297 ARG 297 C LEU 298 n 298 LEU 298 C author_and_software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 C N GLY 13 A N GLY 13 C O GLY 16 A O GLY 16 C N ALA 21 A N ALA 21 C O VAL 30 A O VAL 30 C N LYS 33 A N LYS 33 C O LEU 78 A O LEU 78 C O VAL 79 A O VAL 79 C N LEU 67 A N LEU 67 C N GLN 85 A N GLN 85 C O ILE 135 A O ILE 135 C N LEU 134 A N LEU 134 C O LYS 142 A O LYS 142 1 C CG ARG 36 A CG ARG 36 1 Y 1 C CD ARG 36 A CD ARG 36 1 Y 1 C NE ARG 36 A NE ARG 36 1 Y 1 C CZ ARG 36 A CZ ARG 36 1 Y 1 C NH1 ARG 36 A NH1 ARG 36 1 Y 1 C NH2 ARG 36 A NH2 ARG 36 1 Y 1 C LEU 37 A LEU 37 1 Y 1 C ASP 38 A ASP 38 1 Y 1 C THR 39 A THR 39 1 Y 1 C GLU 40 A GLU 40 1 Y 1 C THR 41 A THR 41 1 Y 1 C GLU 42 A GLU 42 1 Y 1 C GLY 43 A GLY 43 1 Y 1 C GLY 153 A GLY 153 1 Y 1 C VAL 154 A VAL 154 1 Y 1 C PRO 155 A PRO 155 1 Y 1 C VAL 156 A VAL 156 1 Y 1 C ARG 157 A ARG 157 1 Y 1 C THR 158 A THR 158 1 Y 1 C TYR 159 A TYR 159 1 Y 1 C THR 160 A THR 160 1 Y 1 C HIS 161 A HIS 161 1 Y 1 C GLU 162 A GLU 162 1 Y 1 C VAL 163 A VAL 163 1 Y 1 14.12 2.30 115.30 129.42 C C C CA CB CG LEU LEU LEU 166 166 166 N 1 C LYS 6 -65.57 94.49 1 C GLU 8 179.20 158.23 1 C GLU 12 -178.80 141.47 1 C PRO 45 -35.02 119.48 1 C ALA 95 -48.62 -18.03 1 C ARG 126 75.19 -6.69 1 C ASP 127 -147.44 46.33 1 C TYR 179 -108.77 64.92 0.27 0.19 0.19 2.2 8.0 15038 10.0 99.0 RANDOM 1 THROUGHOUT 2 OTHER 2.2 8.0 76 2350 22 0 2252 0.013 1.70 2.200 50.000 1W0X 15044 0.000 0.08000 1 3.300 99.0 refinement X-PLOR 3.1 CYCLIN-DEPENDENT KINASE 2 (E.C.2.7.1.37) Crystal structure of human CDK2 in complex with the inhibitor olomoucine. 1 N N 2 N N 3 N N C PRO 45 A PRO 45 HELX_P C GLU 57 A GLU 57 1 1 13 C LEU 87 A LEU 87 HELX_P C ALA 95 A ALA 95 1 2 9 C PRO 100 A PRO 100 HELX_P C SER 120 A SER 120 1 3 21 C LYS 129 A LYS 129 HELX_P C GLN 131 A GLN 131 5 4 3 C GLY 147 A GLY 147 HELX_P C PHE 152 A PHE 152 1 5 6 C ALA 170 A ALA 170 HELX_P C LEU 175 A LEU 175 1 6 6 C THR 182 A THR 182 HELX_P C ARG 199 A ARG 199 1 7 18 C SER 207 A SER 207 HELX_P C GLY 220 A GLY 220 1 8 14 C GLY 229 A GLY 229 HELX_P C MET 233 A MET 233 5 9 5 C ASP 247 A ASP 247 HELX_P C VAL 252 A VAL 252 1 10 6 C ASP 256 A ASP 256 HELX_P C LEU 267 A LEU 267 1 11 12 C SER 276 A SER 276 HELX_P C ALA 282 A ALA 282 1 12 7 C HIS 283 A HIS 283 HELX_P C VAL 289 A VAL 289 5 13 7 TRANSFERASE PROTEIN KINASE INHIBITORS, CYCLIN-DEPENDENT KINASE, CELL CYCLE REGULATION, CANCER, TRANSFERASE, SERINE/THREONINE -PROTEIN KINASE, ATP-BINDING CDK2_HUMAN UNP 1 P24941 1 298 1W0X 1 298 P24941 C 1 1 298 5 3 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel C PHE 4 A PHE 4 C GLY 13 A GLY 13 C GLY 16 A GLY 16 C ASN 23 A ASN 23 C VAL 29 A VAL 29 C LYS 34 A LYS 34 C LYS 75 A LYS 75 C GLU 81 A GLU 81 C LEU 66 A LEU 66 C THR 72 A THR 72 C GLN 85 A GLN 85 C ASP 86 A ASP 86 C LEU 133 A LEU 133 C ILE 135 A ILE 135 C ILE 141 A ILE 141 C LEU 143 A LEU 143 BINDING SITE FOR RESIDUE OLO C 1299 Software 8 C ILE 10 A ILE 10 8 1_555 C ALA 31 A ALA 31 8 1_555 C GLU 81 A GLU 81 8 1_555 C PHE 82 A PHE 82 8 1_555 C LEU 83 A LEU 83 8 1_555 C ASP 86 A ASP 86 8 1_555 C GLN 131 A GLN 131 8 1_555 C LEU 134 A LEU 134 8 1_555 19 P 21 21 21